NovoCure (NVCR) Non-Current Debt (2015 - 2026)

NovoCure has disclosed Non-Current Debt across 12 years of filings, most recently posting $195.5 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $195.5 million, up 100.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $195.5 million (up 100.58% YoY), and the FY2025 annual result was $195.0 million, up 100.46% from the prior year.
• Non-Current Debt came in at $195.5 million for Q1 2026 at NovoCure, roughly flat from $195.0 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $569.7 million in Q1 2024 to a low of $97.0 million in Q2 2024.
• The 5-year median for Non-Current Debt is $379.2 million (2022), against an average of $350.0 million.
• Across the five-year window, Non-Current Debt slumped 82.9% in 2024 and jumped 100.58% in 2026, its largest moves.
• NovoCure's Non-Current Debt stood at $565.5 million in 2022, then gained by 0.44% to $568.0 million in 2023, then tumbled by 82.87% to $97.3 million in 2024, then jumped by 100.46% to $195.0 million in 2025, then gained by 0.21% to $195.5 million in 2026.
• The last three Non-Current Debt figures came in at $195.5 million (Q1 2026), $195.0 million (Q4 2025), and $194.6 million (Q3 2025), per Business Quant data.